CEO David Ricks can see the companies setting up tents at basecamp behind Eli Lilly in an attempt to get a foothold of the obesity market. But Lilly’s already been to the summit and is coming back down for another trip.

The confetti is still flying from Eli Lilly’s party celebrating the approval of Alzheimer’s disease therapy donanemab, but the company is yet again facing the harsh reality of the neurodegenerative disease with the failure of an early tau-targeting med.

After an FDA rejection last year, Aldeyra Therapeutics has scored a clinical win for dry eye drug reproxalap, which significantly reduced ocular discomfort in a new phase 3 study.

Aminoglycosides are cheap and effective antibiotics that can come with a heavy price—hearing loss. Commonly used in developing countries and for infants in neonatal intensive care, just a few days of treatment can cause these powerful drugs to build up in the inner ear and kill the sensory hair cells that enable hearing, resulting in irreversible damage.

After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next 18 months.

Merck & Co.’s TIGIT program has suffered another setback. Months after shuttering a phase 3 melanoma trial, the Big Pharma has terminated a pivotal lung cancer study after an interim review revealed efficacy and safety problems.

Medical device makers Abbott and Medtronic unveiled a global partnership that pairs Abbott’s continuous glucose monitoring (CGM) sensors with the Medtronic insulin delivery system.

Diality, an Irvine, Calif.-based medical device company focused on renal disease, secured U.S. Food & Drug Administration 510(k) clearance for its new hemodialysis system for acute and chronic renal failure.

Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program.

Novo Nordisk has axed its once-monthly dual GLP-1/GIP receptor agonist, ending (PDF) development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year.